- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Switching from HRT to Non-HRT: Safety Considerations for Menopausal Women
An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.
Hormone replacement therapy (HRT) is routinely used to manage menopausal symptoms, such as vasomotor symptoms (VMS) and night sweats. However, many women going through menopause want a non-hormonal alternative. Elinzanetant is a novel selective nonhormonal dual neurokinin-1,3 (NK-1,3) receptor antagonist being investigated for moderate-to-severe VMS in the phase 3 OASIS clinical trials. Topline data from the OASIS studies show elinzanetant is safe and effective compared to placebo for women during menopause. What, if any, safety concerns should be considered for women currently receiving HRT who may want to switch to elinzanetant? That is what Patient Care Online recently asked JoAnn Pinkerton, MD, national lead for the OASIS clinical trial development program. Her answer in the video below.
Dr Pinkerton is also a professor of obstetrics and gynecology and division director of Midlife Health at the University of Virginia Health System in Charlottesville, Virginia.
Check out part 1 and part 2 of our interview series with Dr Pinkerton for more information on the OASIS studies and elinzanetant.
